Protagonist Therapeutics, Inc. - Common Stock (PTGX)

Competitors to Protagonist Therapeutics, Inc. - Common Stock (PTGX)

AbbVie Inc. 

AbbVie competes with Protagonist Therapeutics in the biopharmaceutical development space, particularly in autoimmunity and oncology. Their significant resources allow them to conduct extensive clinical trials and navigate regulatory pathways more effectively than smaller companies. AbbVie has a solid competitive advantage due to its strong market position with established drugs like Humira, and extensive experience in successfully bringing new therapies to market, which gives it leverage in terms of partnerships and collaborations.

Amgen Inc. 

Amgen is a leader in developing and manufacturing biologics, particularly in the area of targeted therapies for chronic diseases. The company competes with Protagonist Therapeutics through its extensive biologic portfolio and innovation in therapeutic areas like oncology and inflammatory diseases. Amgen has a considerable competitive advantage due to its scale, established market access, and strong R&D capabilities, allowing it to bring therapies to market more efficiently than smaller biotech firms like Protagonist.

Bristol-Myers Squibb Company 

Bristol-Myers Squibb is a major player in the biopharmaceutical sector and competes with Protagonist Therapeutics primarily in the area of developing innovative therapies for autoimmune diseases and cancer. Both companies invest heavily in research and development to advance their pipelines. BMY has a competitive advantage due to its established market presence, extensive resources, and a strong portfolio of approved therapies, which allows it to leverage its size for clinical trials and market entry strategies, while Protagonist is still building its commercial footprint.

Vertex Pharmaceuticals Incorporated 

Vertex Pharmaceuticals is known for its work in genetic diseases, particularly cystic fibrosis, but also has a growing focus on autoimmune and inflammatory diseases. Vertex competes with Protagonist by exploring similar therapeutic areas and advanced treatment modalities, such as oral small molecules and biologics. Although Vertex holds a competitive advantage through its established treatments and significant revenue base, Protagonist’s specialized focus and innovative approach could appeal to niche markets for targeted therapies.